Findings

What do systematic reviews say?

4,752 questions · 6,648 findings · 688 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,125 · 16.9%GRADE not reported 670 · 10.1%Very low 1,796 · 27%Low 1,685 · 25.3%Moderate 1,075 · 16.2%High 297 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Intervention not reported

Laser · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 559 participants
High

Intervention not reported

Bevacizumab · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 261 participants
Low

Intervention not reported

Aflibercept · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 640 participants
Moderate

Intervention not reported

Brolucizumab · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 154 participants
Moderate

Intervention not reported

Bevacizumab · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 261 participants
Moderate

Intervention not reported

Ranibizumab deferred laser · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 136 participants
Moderate

Intervention not reported

Ranibizumab prompt laser · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 136 participants
Moderate

Intervention not reported

Laser · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 563 participants
Moderate

Intervention not reported

Aflibercept · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 2644 participants
Very low

Intervention not reported

Bevacizumab · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 305 participants
Low

Intervention not reported

Brolucizumab · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 368 participants
Low

Intervention not reported

Conbercept · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 125 participants
Very low

Intervention not reported

Brolucizumab · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 154 participants
Low

Intervention not reported

Faricimab · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1262 participants
Low

Intervention not reported

Ranibizumab · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 2065 participants
Low

Intervention not reported

Aflibercept · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 2701 participants
Very low

Intervention not reported

Bevacizumab · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 310 participants
Low

Intervention not reported

Brolucizumab · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 369 participants
Low

Intervention not reported

Conbercept · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 125 participants
Very low

Intervention not reported

Faricimab · people with diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1262 participants
Low